Company Overview of Xcovery LLC
Xcovery LLC, a clinical-stage company, focuses on the development of targeted therapeutics for cancer. It offers Tyrogenex X-82, a VEGFR/PDGFR small molecule inhibitor; and small molecule kinase inhibitors for the treatment of cancer. The company was founded in 2005 and is based in West Palm Beach, Florida.
505 South Flagler Drive
West Palm Beach, FL 33401
Founded in 2005
Key Executives for Xcovery LLC
Chief Executive Officer and President
Vice President of Oncology
Compensation as of Fiscal Year 2014.
Xcovery LLC Key Developments
Xcovery Presents Interim Phase 1 Results of X-396 in ALK positive NSCLC at the American Society for Clinical Oncology Annual Meeting
Jun 3 14
Xcovery presented preliminary results at the annual meeting of the American Society for Clinical Oncology (ASCO) from a phase 1 study of X-396, a potent small molecule anaplastic lymphoma kinase (ALK) inhibitor, that showed X-396 is well tolerated and has antitumor activity in patients with ALK positive non-small cell lung cancer (NSCLC). Xcovery is developing X-396 for the treatment of solid tumors where ALK is deregulated. X-396 has been validated in potency and selectivity assays indicating that it is more selective and up to 10 times more potent than competitive ALK inhibitors. X-396 has been active in animal models of NSCLC and neuroblastoma. Importantly, X-396 has shown activity in ALK mutations that confer resistance to other small molecule ALK inhibitors. Interim results were presented from a dose-escalation phase 1 study evaluating X-396 in patients with advanced solid tumors. Primary study objectives included determining recommended dose of X-396 as a single agent and safety and tolerability of the compound for clinical evaluation going forward. Patients received X-396 daily in 28 day cycles with escalating doses starting at 25 mg daily. At the time of data cutoff, 35 patients were enrolled. Tumor types included NSCLC, head & neck, small cell lung, colorectal, and breast cancers. The NSCLC (n=27) patient group was comprised of ALK-positive patients (n=18) who were either crizotinib-naïve (n=5) or crizotinib-resistant (n=13). Among 11 ALK positive patients evaluable for response (patient completed one cycle and had post baseline response assessment) --6 patients had a partial response (55%) and 2 had stable disease (18%). For the three patients with progressive disease, two were at lower doses (50 mg, 100 mg) with acquired resistance to crizotinib and one (at 250 mg) was resistant to both crizotinib and ceritinib. This crizotinib and ceritinib resistant patient had a complete response in retroperitoneal lymph node but progression of bone and CNS metastases. Common adverse events included low-grade (Grade 1 or 2) nausea, rash, vomiting, fatigue, and edema. Two dose-limiting toxicities (DLTs) were observed: fluid overload (200 mg) and rash (250 mg). X-396 is generally well tolerated at doses up to 250 mg daily. The maximum tolerated dose (MTD) has not been officially reached.
Xcovery LLC Presents at EBD Group's 7th Annual BIO-Europe Spring Conference 2013, Mar-12-2013 11:30 AM
Feb 7 13
Xcovery LLC Presents at EBD Group's 7th Annual BIO-Europe Spring Conference 2013, Mar-12-2013 11:30 AM. Venue: Centre Covencions International Barcelona, Plaça de Willy Brandt, 11-14, 08019 Barcelona, Spain.
Xcovery LLC Presents at Windhover's Therapeutic Area Partnerships Conference, Nov-29-2012 04:40 PM
Nov 27 12
Xcovery LLC Presents at Windhover's Therapeutic Area Partnerships Conference, Nov-29-2012 04:40 PM. Venue: Westin Copley Place, Boston, Massachusetts, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
July 8, 2014
April 11, 2014